Last reviewed · How we verify
SY-5007
SY-5007 is a small molecule that targets the SGLT2 receptor.
SY-5007 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | SY-5007 |
|---|---|
| Also known as | SY-5007 Capsule, SY-5007 tablets |
| Sponsor | Shouyao Holdings (Beijing) Co. LTD |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, SY-5007 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors (PHASE1)
- A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China (PHASE1)
- A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects (PHASE1)
- Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC (PHASE3)
- Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SY-5007 CI brief — competitive landscape report
- SY-5007 updates RSS · CI watch RSS
- Shouyao Holdings (Beijing) Co. LTD portfolio CI